Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Mabpharm Limited ( (HK:2181) ) has provided an announcement.
Mabpharm Limited has announced that its board of directors will convene on March 26, 2025, to review and approve the company’s annual financial results for the year ending December 31, 2024. This meeting is significant as it will address the company’s financial performance and any other business matters, potentially impacting its market positioning and stakeholder interests.
More about Mabpharm Limited
Mabpharm Limited is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. It focuses on the development and commercialization of innovative drugs, primarily targeting the healthcare market.
YTD Price Performance: 96.43%
Average Trading Volume: 109,375
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$2.02B
For a thorough assessment of 2181 stock, go to TipRanks’ Stock Analysis page.